Khimpharm JSC is a pharmaceutical company located in Kazakhstan that has been operating since 1993. It has a large production base and portfolio of over 200 generic and branded medicines. Khimpharm aims to use advanced technologies and qualified specialists to produce high-quality, effective drugs at affordable prices in order to improve public health. It has historically been one of the largest drug producers in Kazakhstan and exports products to countries in Central Asia and Eastern Europe.

1. Khimpharm JSC (SANTO)

2. SANTOLINA has embellished the coat of arms of the town Shymkent since the 21of April 1909.

3. Santonin is a drug which was widely used in the past to expel parasitic worms from the body, by either killing or stunning them. Nowadays Santonin is no longer registered as a drug in most countries. (3 S ,3a S ,5a S ,9b S )-3,5a,9-trimethyl-3a,5,5a,9b-tetrahydronaphtho[1,2- b ]furan-2,8(3 H ,4 H )-dione

4. Brand since 1993…

5. Impetuously developing company , equipped with modern abroad equipment , having new modern technologies in the system of operating production and in marketing VISION

6. Health is the base of any person's happiness . Using the best technologies, the best raw materials and the best specialists we produce effective drugs of high quality at acceptable prices for strengthening people's health and improving life quality in order to give a person an opportunity to feel better , to do more and to live longer . MISSION

8. 200 denominations of generic and original remedies in the form of capsules, tablets, injection solutions in ampoules, syrups, infusions, oil, water and alcohol solutions of 24 pharmacological groups. PRODUCT PORTFOLIO

9. over 50% of domestic drug production in Kazakhstan Market share

12. Polpharma is the majority shareholder since September 2011

13. New brand name

14. $ 85 million investment is only the "first phase"

15. compliance with good manufacturing practice ( GMP ) standards

16. access to over 300 products already in Polpharma's portfolio, and 400 products being developed - mainly in the gastrological, neurological and cardiology therapeutic areas - as well as oncology and biotech drugs .

17. KhimPharm gains the higher level of competitive advantage.

20. WEAKNESSES ? NO!

22. State program for the development of the pharmaceutical industry for 2010-2014 operating in Kazakhstan: in 2014, Kazakhstan’s production of medicines will cover at least 50% of its own market.

23. SK-Pharmatsiya LLP is a single centralized distributor for supplying pharmaceuticals to State health institutions . The share of pharmaceuticals bought through the single distributor system will gradually increase, reaching 70-80% by 2012.

25. opportunity of international expanding

26. ADVANCED TRAINING FOR PERSONNEL

27. Profitability ratios: Items Years 2006 2007 2008 2009 2010 ROE 0,05 0,02 0,10 0,11 0,19 ROS 0,16 0,14 0,16 0,20 0,22 ROA 0,02 0,01 0,04 0,06 0,11 Gross margin rate 0,36 0,35 0,35 0,40 0,41

29. Liquidity ratios: Items Years 2006 2007 2008 2009 2010 Current ratio 0,73 0,75 0,79 1,04 1,48 Acid Test or Quick Ratio 0,29 0,29 0,32 0,42 0,81

31. Asset management ratios: Items Years 2006 2007 2008 2009 2010 AR turnover 4,69 4,71 4,66 5,57 3,73 Days in AR 76,84 76,47 77,22 64,68 96,53 Inventory Turnover 1,78 1,87 2,12 2,29 2,78 Days in Inventory 201,86 192,04 170,11 157,55 129,43 Days in AP 87,25 91,73 32,12 28,75 65,57 Operating expenses 0,14 0,10 0,08 0,11 0,12 Sales growth 0,25 0,18 0,41 0,34

34. Working capital: Working Capital Years 2006 2007 2008 2009 2010 Total LT financing 5 923 978 6 385 193 6 575 661 8 997 608 10 748 766 Total LT investment 5 594 050 5 553 493 6 117 455 5 853 987 6 470 873 Working Capital 329 928 831 700 458 206 3 143 621 4 277 893 Operating cycle needs Years 2006 2007 2008 2009 2010 Total financing of operation 618 369 748 263 320 932 369 914 999 436 Total investments in operation 2 077 431 2 326 617 2 509 905 3 035 164 4 327 967 Operating cycle needs - 1 459 062 - 1 578 354 - 2 188 973 - 2 665 250 - 3 328 531 Working Capital 329 928 831 700 458 206 3 143 621 4 277 893 Operating cycle needs - 1 459 062 - 1 578 354 - 2 188 973 - 2 665 250 - 3 328 531 Difference - 1 129 134 - 746 654 - 1 730 767 478 371 949 362

37. Cash flow ratios: Items Years 2006 2007 2008 2009 2010 Interest coverage ratio 1,03 2,81 2,80 1,29 6,92 Capital Cost Coverage ratio 1,03 2,81 2,79 1,29 6,92 Paid Debt Coverage ratio 0,07 0,29 0,28 0,36 0,69 Total Coverage Ratio 0,07 0,27 0,25 0,28 0,63 Current Liabilities Coverage Ratio 0,11 0,42 0,36 0,48 0,86

39. Items Years 2006 2007 2008 2009 2010 Cash Flow Yield 0,54 1,89 1,21 0,88 0,80 Cash flow to sales 0,09 0,26 0,20 0,18 0,18 Cash flow to asset 0,03 0,13 0,11 0,13 0,14

40. Debt ratios: Items Years 2006 2007 2008 2009 2010 Equity/Debt ratio 0,72 0,78 1,19 1,38 2,88 Equity/Assets 0,33 0,34 0,46 0,51 0,60 Debt/Assets 0,47 0,44 0,39 0,37 0,21

41. Leverage ratios: Items Years 2006 2007 2008 2009 2010 Financial leverage ratio (Debt/equity) 1,40 1,27 0,84 0,73 0,35

42. Based on everything I know about this company and its strategies, the industry and the competitors, and the external factors that will influence the company in the future, do I think this company is worth investing in for the long term ? YES . CONCLUSION